Dr. Mehmet Oz, the TV personality nominated to head the Centers for Medicare & Medicaid Services
Getty Images
Potential Conflicts Arise as Dr. Mehmet Oz Discloses Financial Holdings in Healthcare Stocks
Mehmet Oz, the well-known TV personality and doctor, has been nominated by President-Elect Donald Trump to lead the Centers for Medicare & Medicaid Services. However, concerns have been raised regarding potential conflicts of interest due to Oz’s significant investments in healthcare and health insurance stocks.
According to his 2022 financial disclosure for his Senate run, Oz holds substantial amounts of stock in companies such as UnitedHealth, CVS, Johnson & Johnson, and others. These holdings could potentially impact his decisions while overseeing healthcare programs for millions of Americans.
Kedric Payne from the Campaign Legal Center expressed concerns about Oz’s ability to impartially run drug coverage programs under Medicare and Medicaid, given his financial interests in healthcare companies. He emphasized that Oz’s decisions could influence the value of these stocks while affecting the healthcare of millions.
One of Oz’s largest healthcare holdings is in Sharecare, a digital health and wellness company that he co-founded. The recent acquisition of Sharecare by a private equity firm has further highlighted the potential conflicts of interest that Oz may face in his new role.
Ken Gross, a senior political law counsel, noted that conflicting assets could raise issues with the Office of Government Ethics, regardless of whether Oz undergoes a Senate confirmation hearing. The strict regulations in the executive branch are designed to prevent conflicts of interest for regulators like Oz.
Oz, who previously ran for Pennsylvania’s Senate seat, is known for his TV show where he promoted various health products and treatments. His history of endorsing controversial treatments and supplements has come under scrutiny, raising questions about his suitability to lead a major federal agency like CMS.
Despite his family’s wealth and business ties, it remains unclear whether Oz still holds the healthcare stocks mentioned in his 2022 financial disclosure. As his nomination awaits confirmation by the U.S. Senate, concerns about potential conflicts of interest continue to linger.
Given the current political climate, with calls for expedited appointments, the process of confirming Oz’s appointment may deviate from standard procedures. However, experts like Richard Briffault emphasize the importance of adhering to established rules and regulations in such appointments.
As the debate surrounding Dr. Mehmet Oz’s nomination unfolds, the spotlight remains on the potential conflicts of interest that could impact his ability to effectively lead the Centers for Medicare & Medicaid Services.
